Esomeprazole + Lansoprazole
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Barrett's Esophagus
Conditions
Barrett's Esophagus
Trial Timeline
Jan 1, 2006 → Apr 1, 2007
NCT ID
NCT00352261About Esomeprazole + Lansoprazole
Esomeprazole + Lansoprazole is a approved stage product being developed by AstraZeneca for Barrett's Esophagus. The current trial status is completed. This product is registered under clinical trial identifier NCT00352261. Target conditions include Barrett's Esophagus.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00352261 | Approved | Completed |
| NCT00644735 | Approved | Completed |
| NCT00641602 | Approved | Completed |
Competing Products
3 competing products in Barrett's Esophagus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Esomeprazole + Aspirin + Rofecoxib | AstraZeneca | Approved | 85 |
| Esomeprazole Magnesium | AstraZeneca | Approved | 85 |
| Chemotherapy | Pacific Biosciences | Pre-clinical | 15 |